AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer.
AsclepiX Therapeutics has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
AsclepiX Therapeutics's investors include TEDCO, Perceptive Advisors, Salem Partners, Rapha Capital Management, Piedmont Capital Partners.
AsclepiX Therapeutics is headquartered in Baltimore, United States.
AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer.
AsclepiX Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AsclepiX Therapeutics — Funding & Investors." VCBacked, July 26, 2023, https://www.vcbacked.co/company/asclepix-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). AsclepiX Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/asclepix-therapeutics
{{cite web |title=AsclepiX Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/asclepix-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated